Austin Texas based QSAM Biosciences is raising $2,500,000.00 in New Equity Investment.
Austin, TX – According to filings with the U.S. Securities and Exchange Commission, QSAM Biosciences is raising $2,500,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Douglas Baum played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.
About QSAM Biosciences
QSAM Biosciences, Inc. is developing next generation nuclear medicines for the treatment of cancer and related diseases and conditions. QSAM’s initial technology is Samarium-153 DOTMP, aka CycloSam, a clinical-staged bone targeting radiopharmaceutical developed by IsoTherapeutics Group LLC, leaders in the nuclear medicine space who also developed FDA-approved and commercially available Quadramet (Samarium-153 EDTMP), indicated for pain palliation. CycloSam was assigned to IsoTherapeutics Group’s subsidiary, IGL Pharma, Inc.
To learn more about QSAM Biosciences, visit http://qsambio.com/
Contact:
Douglas Baum, Chief Executive Officer
512-343-4558
https://www.linkedin.com/in/doug-baum-132923/
SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved